Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Catagrev
- Development stage
- Unknown
- Lead developer
- Grevis Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Catagrev is an ophthalmic solution (eye drops) developed by Grevis Pharma. It is a fixed-dose combination containing potassium iodide (3.3% w/v), sodium chloride (0.83% w/v), and calcium chloride (1.0% w/v). Catagrev is indicated for the management and supportive care of cataracts, specifically to delay cataractogenesis (the progression of lenticular opacity) and to prevent posterior capsular opacification (PCO) post-operatively. The combination works by restoring ionic and electrolyte balance across the lens membrane, supporting lens metabolism, and providing antioxidant defense to protect the lens from oxidative damage.
- Brand names
- Catagrev
Beyond the preview
Go deeper on Catagrev.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Catagrev.